Human placental extract treatment for non‐alcoholic steatohepatitis non‐responsive to lifestyle intervention: A pilot study

No pharmacological therapies have been established for non‐alcoholic steatohepatitis (NASH), which can lead to liver‐related mortality. Human placental extract (HPE), which has anti‐inflammatory effects, has been expected to be a promising treatment for chronic liver disease. This pilot study was conducted to evaluate the efficacy of HPE for biopsy‐diagnosed NASH.

[1]  T. Fukui,et al.  Antioxidative collagen-derived peptides in human-placenta extract. , 2002, Placenta.

[2]  S. Park,et al.  Anti-oxidative and anti-inflammatory activities of placental extracts in benzo[a]pyrene-exposed rats. , 2010, Placenta.

[3]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[4]  K. Yum,et al.  Efficacy and Safety of Human Placental Extract Solution on Fatigue: A Double-Blind, Randomized, Placebo-Controlled Study , 2011, Evidence-based complementary and alternative medicine : eCAM.

[5]  Y. Sugiyama,et al.  Human placental extract stimulates liver regeneration in rats. , 1998, Biological & pharmaceutical bulletin.

[6]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[7]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.

[8]  A. Diehl,et al.  Mechanisms of disease progression in NASH: new paradigms. , 2012, Clinics in liver disease.

[9]  Eun-Ju Lee,et al.  Effect of human placental extract on menopausal symptoms, fatigue, and risk factors for cardiovascular disease in middle-aged Korean women , 2008, Menopause.

[10]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[11]  J. Shaw,et al.  Validation of the non‐alcoholic fatty liver disease activity score , 2011, Alimentary pharmacology & therapeutics.

[12]  E. Niki,et al.  Involvement of free radicals and oxidative stress in NAFLD/NASH , 2013, Free radical research.

[13]  B. Neuschwander‐Tetri,et al.  Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings , 2011, Hepatology.

[14]  A. Bishayee,et al.  Anti-inflammatory effect of human placental extract: a biochemical mechanistic approach. , 1992, Rivista europea per le scienze mediche e farmacologiche = European review for medical and pharmacological sciences = Revue europeenne pour les sciences medicales et pharmacologiques.

[15]  S. Park,et al.  Effect of Human Placental Extract on Health Status in Elderly Koreans , 2012, Evidence-based complementary and alternative medicine : eCAM.

[16]  Jung Min Lee,et al.  Placenta extract promote liver regeneration in CCl4-injured liver rat model. , 2011, International immunopharmacology.

[17]  P. Giral,et al.  Sampling variability of liver biopsy in nonalcoholic fatty liver disease. , 2005, Gastroenterology.

[18]  M. Horiguchi,et al.  Efficacy of CE14 (human placenta preparation) in a double blind trial on chronic liver diseases , 1974 .

[19]  N. Bhattacharya,et al.  Wound healing activity of human placental extracts in rats. , 2001, Acta pharmacologica Sinica.

[20]  K. Oguchi,et al.  [A comparative study of human placenta hydrolysate (Laennec) by intravenous or subcutaneous injection on liver regeneration after partial hepatectomy in normal and CCl4-induced cirrhosis rats]. , 1989, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[21]  K. Oguchi,et al.  [A comparative study of Laennec by intravenous or subcutaneous injection on CCl4-induced acute or chronic liver injury in rats]. , 1989, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[22]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[23]  Jinyong Peng,et al.  Protective effect of JBP485 on concanavalin A‐induced liver injury in mice , 2009, The Journal of pharmacy and pharmacology.

[24]  N. Kawada,et al.  Inflammation and fibrogenesis in steatohepatitis , 2012, Journal of Gastroenterology.

[25]  L. Ferrell,et al.  Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease , 2006, Hepatology.

[26]  Huijun Sun,et al.  Protective effect of JBP485 on concanavalin A-induced hepatocyte toxicity in primary cultured rat hepatocytes. , 2008, European journal of pharmacology.

[27]  Michael Charlton,et al.  The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. , 2012, Gastroenterology.

[28]  Huijun Sun,et al.  Laennec protects murine from concanavalin A-induced liver injury through inhibition of inflammatory reactions and hepatocyte apoptosis. , 2008, Biological & pharmaceutical bulletin.